Mechanistic kidney effects of semaglutide by baseline SGLT2i use in type 2 diabetes: a post-hoc analysis of the REMODEL trial
Authors:
David Z.I. Cherney1; Radica Z. Alicic2,3; Milenta M. Chacko4; Lynette Driscoll5; Emma T.B. Olesen6; Prachi Priyardarshini7; Vikas S. Sridhar8; Katherine R. Tuttle1,2,9; Petter Bjornstad10,11